As priorities evolve, single-use technologies are enabling more flexible facilities, hybrid manufacturing strategies, and the next generation of biopharmaceutical production.
The collaboration with the CDMO covers Phase 3 clinical supply and commercial manufacturing for Arcturus Therapeutics’ investigational cystic fibrosis therapy.
UV is a comprehensive solution for chloramine reduction and can work synergistically with activated carbon, helping to reduce waste, lower operating costs, and minimize the amount of carbon needed over time.
